[go: up one dir, main page]

MX2018011837A - Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas. - Google Patents

Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas.

Info

Publication number
MX2018011837A
MX2018011837A MX2018011837A MX2018011837A MX2018011837A MX 2018011837 A MX2018011837 A MX 2018011837A MX 2018011837 A MX2018011837 A MX 2018011837A MX 2018011837 A MX2018011837 A MX 2018011837A MX 2018011837 A MX2018011837 A MX 2018011837A
Authority
MX
Mexico
Prior art keywords
compositions
alphaviruses
methods
stabilizing
live
Prior art date
Application number
MX2018011837A
Other languages
English (en)
Inventor
Ann Livengood Jill
Duane Powell Timothy
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2018011837A publication Critical patent/MX2018011837A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las modalidades aquí se refieren a las composiciones y métodos para estabilizar los alfavirus vivos. Otras modalidades se refieren a composiciones y métodos para reducir la degradación de alfavirus atenuados vivos. Ciertas modalidades se refieren a proporcionar una composición estabilizante mi entras se reduce la reacción inmune en un sujeto a excipientes que estabilizan los alfavirus vivos proporcionando formulaciones mejoradas. Todavía otras modalidades se refieren a usos de composiciones descritas aquí en kits para aplicaciones portátiles y métodos en donde las composiciones reducen la degradación de los alfavirus vivos.
MX2018011837A 2016-03-31 2017-03-27 Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas. MX2018011837A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316262P 2016-03-31 2016-03-31
PCT/US2017/024365 WO2017172643A1 (en) 2016-03-31 2017-03-27 Compositions and methods for stabilizing alphaviruses with improved formulations

Publications (1)

Publication Number Publication Date
MX2018011837A true MX2018011837A (es) 2019-02-13

Family

ID=58537071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011837A MX2018011837A (es) 2016-03-31 2017-03-27 Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas.

Country Status (19)

Country Link
US (2) US10632184B2 (es)
EP (1) EP3436063A1 (es)
JP (1) JP2019513138A (es)
KR (1) KR20180135912A (es)
CN (1) CN109069614A (es)
AU (1) AU2017241590A1 (es)
BR (1) BR112018069035A2 (es)
CA (1) CA3019529A1 (es)
CO (1) CO2018010357A2 (es)
CR (1) CR20180456A (es)
DO (1) DOP2018000211A (es)
EC (1) ECSP18081486A (es)
MX (1) MX2018011837A (es)
NI (1) NI201800096A (es)
PE (1) PE20190149A1 (es)
PH (1) PH12018502119A1 (es)
SG (1) SG11201808458QA (es)
SV (1) SV2018005747A (es)
WO (1) WO2017172643A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10538785B2 (en) 2013-12-23 2020-01-21 Renaud Vaillant Lyophilized lentiviral vector particles, compositions and methods
AU2020328159A1 (en) * 2019-08-09 2022-01-27 Valneva Se Single shot Chikungunya virus vaccine
WO2021028406A1 (en) * 2019-08-09 2021-02-18 Valneva Se Chikungunya vaccine formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545555A (en) 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
EP2073839B1 (en) 2006-09-01 2016-10-19 Bharat Biotech International Limited A vaccine for chikungunya virus infection
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
MX361342B (es) * 2013-03-14 2018-12-04 Takeda Vaccines Inc Composiciones y metodos para formulaciones de alfavirus vivos atenuados.
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗

Also Published As

Publication number Publication date
BR112018069035A2 (pt) 2019-01-29
KR20180135912A (ko) 2018-12-21
US20200306361A1 (en) 2020-10-01
ECSP18081486A (es) 2019-01-31
CA3019529A1 (en) 2017-10-05
NI201800096A (es) 2019-02-01
CR20180456A (es) 2019-01-09
DOP2018000211A (es) 2018-12-31
WO2017172643A1 (en) 2017-10-05
SG11201808458QA (en) 2018-10-30
CO2018010357A2 (es) 2019-05-21
PH12018502119A1 (en) 2019-07-15
PE20190149A1 (es) 2019-01-22
SV2018005747A (es) 2019-03-28
CN109069614A (zh) 2018-12-21
JP2019513138A (ja) 2019-05-23
EP3436063A1 (en) 2019-02-06
AU2017241590A1 (en) 2018-10-11
US10632184B2 (en) 2020-04-28
US20190111124A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
ZA201802331B (en) Stable inoculant compositions and methods for producing same
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2017004617A (es) Variantes estabilizadas de alfa amilasa y su uso.
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
MX2016016281A (es) Polipeptidos receptores formulados y metodos relacionados.
MX2019004611A (es) Metodos y composiciones para cambiar la composicion del microbioma de la piel usando mezclas complejas de cepas bacterianas.
MX2017009720A (es) Composiciones de oligosacaridos para el uso en composiciones nutricionales y metodos para producirlas.
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
MX369223B (es) Composiciones de protector solar.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
PH12017500836A1 (en) Transdermal formulations
MX2018016037A (es) Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa.
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
EP4292652A3 (en) Compounds for the treatment of glycogen storage disorders
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
GB2568181A (en) Wheat
PH12018502119A1 (en) Compositions and methods for stabilizing alphaviruses with improved formulations
MX2019013642A (es) Compuestos, composiciones y metodos.
PH12015502115B1 (en) Compositions and methods for live, attenuated alphavirus formulations
CA3056612A1 (en) Analogs of deutetrabenazine, their preparation and use
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
UA88646U (uk) Перфторароматичні ізомерні дифторфенілазометинфенілові етери як мономери для поліетеразометинів